top of page
  • Writer's pictureANPDF

Intrabio Media Release | December 5, 2022

Updated: Jan 11, 2023

"IntraBio Ltd. is pleased to confirm that it has completed recruitment for its Pivotal Trial, Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study (IB1001-301 - NCT05163288)."

Read the full article here:

IB1001-301 Recruitment Complete
Download PDF • 125KB

  • 70+ NPC patients were screened across 13 trial sites in Australia, Europe, United Kingdom and United States.

  • The trial was able to be over-enrolled by approximately 130% and the data-read is expected out in June 2023.

  • Multiple Australian patients were recruited and will have their first screening visit this month!


To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."

Ways to support NP-C in Australia:

31 views0 comments

Recent Posts

See All


Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page